WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Understanding Parkinson's Disease: Insights into Genetics and Pathophysiology

***Mansi Bhingaradiya*[1]**

[1]Smt C.V Gajera Pharmacy Mahila College, Amreli, 365601, Gujrat

ABSTRACT:

Parkinson's disease (PD) is a complex brain disorder causing the gradual loss of certain brain cells, leading to movement difficulties and other symptoms. While the exact cause is not fully understood, both genetic factors and environmental influences are believed to contribute to its development. This review aims to provide a comprehensive summary of what we currently know about the genetics and underlying mechanisms of PD. We discuss the findings from genetic studies, which have identified specific genes and variations associated with PD risk. Additionally, we explore the processes within the brain that go awry in PD, including protein buildup, problems with cell energy, oxidative stress, and inflammation. Understanding these aspects of PD is crucial for developing better treatments to slow down or halt its progression.

Introduction:

Parkinson's disease (PD) stands as one of the most prevalent neurodegenerative disorders, affecting millions globally. Despite extensive research, its exact causes remain elusive, presenting a multifaceted interplay between genetic predisposition and environmental factors. This review aims to delve into the intricate landscape of PD, elucidating the amalgamation of genetic intricacies and the pathophysiological underpinnings that contribute to its onset and progression.

PD's complexity arises from its heterogeneous nature, with symptoms ranging from motor impairments to non-motor symptoms such as cognitive decline and psychiatric disturbances. While age remains the most significant risk factor, recent advances have highlighted the crucial role of genetics in predisposing individuals to the disease. Genetic studies, spanning from familial forms to large-scale genome-wide association studies (GWAS), have unraveled a spectrum of genetic variants implicated in PD susceptibility.

Furthermore, environmental factors such as pesticide exposure, head trauma, and certain medications have been implicated in PD pathogenesis. However, their interactions with genetic predispositions remain poorly understood, underscoring the need for integrated approaches to decipher PD's etiology comprehensively.

Understanding PD's genetic architecture is pivotal for unraveling its underlying molecular mechanisms. Key genetic discoveries, including mutations in genes encoding α-synuclein (SNCA), leucine-rich repeat kinase 2 (LRRK2), parkin (PARK2), PTEN-induced kinase 1 (PINK1), and DJ-1 (PARK7), have provided invaluable insights into the molecular pathways underpinning PD pathology. Additionally, GWAS have identified common genetic variants associated with PD risk, shedding light on novel biological pathways implicated in disease susceptibility.

However, elucidating the genetic basis of PD represents only one facet of the disease's complexity. The pathological hallmarks of PD, including the formation of Lewy bodies—abnormal protein aggregates primarily composed of α-synuclein—underscore the role of protein misfolding and aggregation in neurodegeneration. Moreover, mitochondrial dysfunction, oxidative stress, impaired protein degradation pathways, and neuroinflammation have emerged as critical players in PD pathophysiology, highlighting the intricate network of cellular processes disrupted in the disease state.

In essence, PD embodies a multifaceted interplay between genetic predisposition, environmental exposures, and underlying molecular mechanisms. A comprehensive understanding of these complexities is essential for unraveling PD's mysteries and developing targeted therapeutic interventions to alleviate its burden on patients and society.

Risks of Parkinson's Disease:

Parkinson's disease (PD) is influenced by a combination of genetic, environmental, and lifestyle factors. While the exact causes of PD remain elusive, several risk factors have been identified through epidemiological studies and clinical observations. Understanding these risk factors is crucial for identifying individuals at higher risk of developing PD and implementing preventive measures where possible.

1. Age:

Advancing age is the most significant risk factor for PD. The prevalence of PD increases with age, with the majority of cases diagnosed after the age of 60. While PD can occur in younger individuals (known as early-onset PD), the risk significantly rises with each decade of life.

2. Genetic Factors:

Genetic predisposition plays a role in PD susceptibility, particularly in familial forms of the disease. Mutations in specific genes, such as SNCA, LRRK2, PARKIN, PINK1, and DJ-1, have been associated with an increased risk of PD. Additionally, common genetic variants identified through genome-wide association studies (GWAS) contribute to the overall genetic risk of PD.

3. Environmental Exposures:

Exposure to certain environmental toxins and chemicals has been linked to an increased risk of PD. Pesticides and herbicides, including paraquat and rotenone, have been implicated as potential environmental risk factors for PD. Other environmental factors, such as heavy metals (e.g., lead and manganese) and industrial solvents, may also contribute to PD risk.

4. Head Trauma:

Traumatic brain injury, particularly repetitive head trauma, has been associated with an increased risk of PD. Studies have shown that individuals with a history of head trauma, such as those involved in contact sports or military service, may have a higher risk of developing PD later in life.

5. Family History:

A family history of PD increases an individual's risk of developing the disease. While most cases of PD are sporadic, meaning they occur in individuals with no family history, familial clustering of PD suggests a genetic component in certain cases. Having a first-degree relative (parent or sibling) with PD increases the risk of developing the disease.

6. Gender:

Men are slightly more likely to develop PD than women, although the reasons for this gender difference are not fully understood. Some studies suggest hormonal factors may play a role in modulating PD risk, but further research is needed to elucidate the underlying mechanisms.

7. Smoking and Coffee Consumption:

Interestingly, cigarette smoking and coffee consumption have been associated with a reduced risk of developing PD. While the exact mechanisms underlying this protective effect are not fully understood, certain compounds found in tobacco and caffeine may exert neuroprotective effects against PD.

8. Other Medical Conditions:

Certain medical conditions, such as diabetes, cardiovascular disease, and depression, have been linked to an increased risk of PD. Chronic inflammation, metabolic dysfunction, and altered neurotransmitter levels associated with these conditions may contribute to PD pathogenesis.

Understanding these risk factors is essential for identifying individuals at higher risk of developing PD and implementing preventive strategies, such as lifestyle modifications and early intervention programs. Additionally, ongoing research into the underlying mechanisms of PD will provide further insights into disease prevention and treatment strategies.

Genetics of Parkinson’s Disease:

Parkinson’s disease (PD) is recognized as a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the substantia nigra region of the brain, resulting in motor symptoms such as tremors, rigidity, bradykinesia, and postural instability. While environmental factors play a role in PD, genetic factors have gained significant attention in unraveling the disease's etiology and pathogenesis.

1. Monogenic Forms of PD:

Monogenic forms of PD, accounting for approximately 5-10% of all PD cases, are characterized by mutations in specific genes inherited in a Mendelian fashion. Key genes implicated in monogenic PD include:

- SNCA (Alpha-synuclein): Mutations and multiplications in the SNCA gene, encoding the α-synuclein protein, are associated with autosomal dominant forms of PD. α-synuclein aggregation is a hallmark pathological feature of PD.

- LRRK2 (Leucine-rich repeat kinase 2): LRRK2 mutations represent the most common genetic cause of familial and sporadic PD, particularly in certain ethnic populations. LRRK2 encodes a kinase enzyme implicated in various cellular processes, including vesicle trafficking and autophagy.

- PARKIN (Parkin RBR E3 ubiquitin protein ligase): Loss-of-function mutations in the PARKIN gene lead to autosomal recessive juvenile-onset PD. Parkin functions as an E3 ubiquitin ligase, targeting proteins for degradation via the ubiquitin-proteasome system.

- PINK1 (PTEN-induced kinase 1): Mutations in the PINK1 gene cause autosomal recessive early-onset PD. PINK1 plays a critical role in mitochondrial quality control and mitophagy, the process of selectively removing damaged mitochondria.

- DJ-1 (Parkinson protein 7): Mutations in the DJ-1 gene are associated with autosomal recessive early-onset PD. DJ-1 functions as a cytoprotective antioxidant protein, regulating cellular oxidative stress response pathways.

2. Genome-Wide Association Studies (GWAS):

GWAS have identified common genetic variants associated with an increased risk of sporadic PD. These variants typically exert modest effects on PD susceptibility and are found in genes involved in various biological pathways, including:

- SNCA, LRRK2, and GBA (Glucosylceramidase Beta): Variants in these genes are associated with increased PD risk, further highlighting the importance of α-synuclein metabolism and lysosomal function in PD pathogenesis.

- MAPT (Microtubule-associated protein tau): Variants in the MAPT gene, encoding the tau protein, have been linked to PD risk, implicating aberrant protein aggregation and microtubule dynamics in disease pathology.

- HLA (Human leukocyte antigen) region: Variants in the HLA region, involved in immune response regulation, have been associated with PD risk, suggesting a role for neuroinflammation in disease progression.

Understanding the genetic architecture of PD has profound implications for disease diagnosis, prognosis, and the development of targeted therapies. However, the complex interplay between genetic and environmental factors in PD pathogenesis necessitates further research to elucidate disease mechanisms comprehensively and identify novel therapeutic targets.

Pathophysiology of Parkinson's Disease:

Parkinson's disease (PD) is characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to a cascade of pathological changes within the brain. The intricate interplay of various cellular mechanisms contributes to the clinical manifestations of PD, including motor impairments, cognitive dysfunction, and psychiatric symptoms. Understanding the pathophysiology of PD is essential for developing targeted therapeutic strategies to halt or slow disease progression.

1. Alpha-synuclein Aggregation:

The hallmark pathological feature of PD is the accumulation of misfolded alpha-synuclein protein aggregates, known as Lewy bodies, within neurons. Alpha-synuclein aggregation disrupts normal cellular function, leading to impaired neurotransmitter release, synaptic dysfunction, and ultimately neuronal death.

2. Mitochondrial Dysfunction:

Mitochondrial dysfunction plays a central role in PD pathogenesis. Impaired mitochondrial bioenergetics, oxidative stress, and defective mitochondrial dynamics contribute to neuronal vulnerability and cell death. Mutations in PD-associated genes, such as PINK1 and PARKIN, disrupt mitochondrial quality control mechanisms, leading to mitochondrial dysfunction and neuronal degeneration.

3. Oxidative Stress:

Oxidative stress, resulting from an imbalance between reactive oxygen species (ROS) production and antioxidant defense mechanisms, is a key contributor to PD pathology. Dopaminergic neurons are particularly vulnerable to oxidative damage due to the metabolism of dopamine and the presence of iron-rich neuromelanin. Oxidative stress leads to protein and lipid peroxidation, DNA damage, and mitochondrial dysfunction, exacerbating neuronal degeneration in PD.

4. Impaired Protein Degradation Pathways:

Dysregulation of protein degradation pathways, including the ubiquitin-proteasome system and autophagy-lysosomal pathway, contributes to the accumulation of misfolded proteins in PD. Mutations in genes encoding proteins involved in these pathways, such as PARKIN and LRRK2, disrupt protein clearance mechanisms, leading to protein aggregation and neuronal toxicity.

5. Neuroinflammation:

Chronic neuroinflammation is a prominent feature of PD pathology, characterized by microglial activation, astrocyte reactivity, and the release of pro-inflammatory cytokines and chemokines. Neuroinflammation exacerbates neuronal damage and contributes to disease progression by amplifying oxidative stress, promoting alpha-synuclein aggregation, and impairing synaptic function.

6. Dysregulated Neurotransmission:

Dysfunction of neurotransmitter systems, particularly the dopaminergic and cholinergic systems, contributes to the motor and non-motor symptoms of PD. Dopamine depletion in the striatum leads to motor impairments, while alterations in acetylcholine levels contribute to cognitive dysfunction and psychiatric symptoms.

Overall, the pathophysiology of PD is characterized by a complex interplay of molecular, cellular, and neurochemical changes that culminate in the progressive degeneration of dopaminergic neurons and the onset of motor and non-motor symptoms. Targeting these underlying mechanisms holds promise for the development of disease-modifying therapies to slow or halt disease progression in PD.

Conclusion :

Parkinson's disease (PD) is a complex neurodegenerative disorder influenced by genetic susceptibility, environmental factors, and lifestyle choices. Genetic studies have identified key genes and pathways involved in PD pathogenesis, highlighting the importance of protein aggregation, mitochondrial dysfunction, oxidative stress, and neuroinflammation. However, PD risk is also influenced by environmental exposures and other factors, emphasizing the need for comprehensive preventive measures. Despite advancements, current treatments focus on symptom management, underscoring the urgent need for disease-modifying therapies. Moving forward, a multidisciplinary approach integrating genetics, neuroscience, and translational medicine is crucial for advancing our understanding of PD and developing effective treatments to improve patient outcomes.

Reference:

1. Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017). Selective neuronal vulnerability in Parkinson disease. Nature Reviews Neuroscience, 18(2), 101–113. doi:10.1038/nrn.2016.178
2. Hernandez, D. G., & Reed, X. (2016). Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance. Journal of Neurochemistry, 139(Suppl 1), 59–74.
3. Dorsey, E. R., Bloem, B. R., & Okun, M. S. (2021). The past, present, and future of Parkinson’s disease: A special essay on the 200th Anniversary of the Shaking Palsy. Movement Disorders, 36(1), 4–16. doi:10.1002/mds.28363
4. Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A. E., & Lang, A. E. (2017). Parkinson disease. Nature Reviews Disease Primers, 3, 17013. doi:10.1038/nrdp.2017.13
5. Ascherio, A., & Schwarzschild, M. A. (2016). The epidemiology of Parkinson’s disease: Risk factors and prevention. The Lancet Neurology, 15(12), 1257–1272. doi:10.1016/S1474-4422(16)30230-7
6. Kalia, L. V., & Lang, A. E. (2015). Parkinson's disease. The Lancet, 386(9996), 896–912. doi:10.1016/S0140-6736(14)61393-3
7. Dauer, W., & Przedborski, S. (2003). Parkinson’s disease: Mechanisms and models. Neuron, 39(6), 889–909. doi:10.1016/S0896-6273(03)00568-3
8. Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017). Non-motor features of Parkinson disease. Nature Reviews Neuroscience, 18(7), 435–450. doi:10.1038/nrn.2017.62
9. Nalls, M. A., Pankratz, N., Lill, C. M., Do, C. B., Hernandez, D. G., Saad, M., DeStefano, A. L., Kara, E., Bras, J., Sharma, M., Schulte, C., Keller, M. F., Arepalli, S., Letson, C., Edsall, C., Stefansson, H., Liu, X., Pliner, H., Lee, J. H., ... Singleton, A. B. (2014). Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nature Genetics, 46(9), 989–993. doi:10.1038/ng.3043
10. Fearnley, J. M., & Lees, A. J. (1991). Ageing and Parkinson’s disease: Substantia nigra regional selectivity. Brain, 114(5), 2283–2301. doi:10.1093/brain/114.5.2283
11. Gao, H. M., & Hong, J. S. (2008). Why neurodegenerative diseases are progressive: Uncontrolled inflammation drives disease progression. Trends in Immunology, 29(8), 357–365.
12. Tanner, C. M., Goldman, S. M., Ross, G. W., Grate, S. J., & Mayeux, R. (2014). The disease intersection of susceptibility and exposure: Chemical exposures and neurodegenerative disease risk. Alzheimer's & Dementia, 10(3), S213–S225. doi:10.1016/j.jalz.2013.12.015
13. Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., & Deuschl, G. (2015). MDS clinical diagnostic criteria for Parkinson’s disease. Movement Disorders, 30(12), 1591–1601. doi:10.1002/mds.26424
14. Kalia, L. V., & Kalia, S. K. (2015). Alpha-synuclein and Lewy pathology in Parkinson’s disease. Current Opinion in Neurology, 28(4), 375–381. doi:10.1097/WCO.0000000000000228
15. Hirsch, E. C., & Jenner, P. (2018). Prion-like mechanisms in Parkinson’s disease. Movement Disorders, 33(3), 349–358. doi:10.1002/mds.27323
16. Subramaniam, S. R., & Chesselet, M. F. (2013). Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Progress in Neurobiology, 106-107, 17–32. doi:10.1016/j.pneurobio.2013.04.004
17. Lang, A. E., & Lozano, A. M. (1998). Parkinson's disease: Second of two parts. New England Journal of Medicine, 339(16), 1130–1143. doi:10.1056/NEJM199810153391607

18. Braak, H., & Del Tredici, K. (2017). Neuropathological staging of brain pathology in sporadic Parkinson's disease: Separating the wheat from the chaff. Journal of Parkinson's Disease, 7(s1), S73–S87. doi:10.3233/JPD-179001

19. Goldman, S. M. (2014). Environmental toxins and Parkinson's disease. Annual Review of Pharmacology and Toxicology, 54, 141–164. doi:10.1146/annurev-pharmtox-011613-135937

20. De Lau, L. M., & Breteler, M. M. (2006). Epidemiology of Parkinson's disease. The Lancet Neurology, 5(6), 525–535. doi:10.1016/S1474-4422(06)70471-9

21. Guo, J. F., & Wu, R. M. (2018). Genetic factors in the pathogenesis of Parkinson's disease. Movement Disorders, 33(12), 1857–1870. doi:10.1002/mds.27588

22. Bellucci, A., Mercuri, N. B., Venneri, A., Faustini, G., Longhena, F., Pizzi, M., Missale, C., Spano, P., & Pizzi, M. (2016). Review: Parkinson's disease: From synaptic loss to connectome dysfunction. Neuropathology and Applied Neurobiology, 42(1), 77–94.

23. Beitz, J. M. (2014). Parkinson's disease: A review. Frontiers in Bioscience (Scholar Edition), 6, 65–74. doi:10.2741/S415

24. Shulman, L. M., & De Jager, P. L. (2017). Evidence for a common pathway linking neurodegenerative diseases. Nature Genetics, 49(12), 1786–1787. doi:10.1038/ng.4027

25. Hirsch, E. C. (2019). Metabolic and cell survival pathways in Parkinson's disease. Neurology, 92(9), 373–383. doi:10.1212/WNL.0000000000006862

26. Gelders, G., Baekelandt, V., & Van der Perren, A. (2018). Linking neuroinflammation and neurodegeneration in Parkinson's disease. Journal of Immunology Research, 2018, 4784268. doi:10.1155/2018/4784268

27. Lees, A. J. (2007). Unresolved issues relating to the shaking palsy on the celebration of James Parkinson's 250th birthday. Movement Disorders, 22(S17), S327–S334. doi:10.1002/mds.21632

28. Dickson, D. W. (2012). Parkinson's disease and parkinsonism: Neuropathology. Cold Spring Harbor Perspectives in Medicine, 2(8), a009258.

29. Tysnes, O. B., & Storstein, A. (2017). Epidemiology of Parkinson's disease. Journal of Neural Transmission, 124(8), 901–905. doi:10.1007/s00702-017-1686-y

30. Tolosa, E., Gaig, C., & Santamaría, J. (2009). Comorbidity in Parkinson's disease. Journal of Neurology, 256(Suppl 3), 33–38. doi:10.1007/s00415-009-3005-4 .